Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) is projected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($2.38) per share and revenue of $5.30 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Thursday, March 12th. The company reported ($3.98) EPS for the quarter, missing the consensus estimate of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.The firm had revenue of $5.39 million for the quarter, compared to the consensus estimate of $2.97 million. On average, analysts expect Tonix Pharmaceuticals to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Up 0.1%

Tonix Pharmaceuticals stock traded up $0.02 during trading on Monday, hitting $13.62. The stock had a trading volume of 254,563 shares, compared to its average volume of 406,189. Tonix Pharmaceuticals has a 1 year low of $11.60 and a 1 year high of $69.97. The stock’s 50 day moving average is $13.77 and its two-hundred day moving average is $15.95. The stock has a market cap of $182.56 million, a price-to-earnings ratio of -0.95 and a beta of 1.68.

Insider Transactions at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 15,000 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was acquired at an average cost of $14.89 per share, for a total transaction of $223,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TNXP. Legal & General Group Plc bought a new position in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $25,000. State of Wyoming bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of Tonix Pharmaceuticals during the third quarter valued at approximately $29,000. BNP Paribas Financial Markets purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $65,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $104,000. 82.26% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $22.00 price target on the stock. Wall Street Zen cut shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tonix Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $22.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.